Which has preferable earnings & valuation, HAE or DXCM?

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 2.29 $97.31M $2.02 33.31 DexCom $4.66B 6.08 $836.30M $2.34 31.39

Is HAE or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Haemonetics' net margin of 7.29%. DexCom's return on equity of 33.33% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.29% 27.30% 9.59% DexCom 19.31% 33.33% 13.19%

Does the media prefer HAE or DXCM?

In the previous week, DexCom had 25 more articles in the media than Haemonetics. MarketBeat recorded 28 mentions for DexCom and 3 mentions for Haemonetics. DexCom's average media sentiment score of 1.00 beat Haemonetics' score of 0.28 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 21 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to HQY or HAE?

In the previous week, HealthEquity had 11 more articles in the media than Haemonetics. MarketBeat recorded 14 mentions for HealthEquity and 3 mentions for Haemonetics. HealthEquity's average media sentiment score of 0.69 beat Haemonetics' score of 0.28 indicating that HealthEquity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, LNTH or HAE?

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.21 $233.56M $4.15 24.05 Haemonetics $1.33B 2.29 $97.31M $2.02 33.31

Is LNTH or HAE more profitable?

Lantheus has a net margin of 18.05% compared to Haemonetics' net margin of 7.29%. Lantheus' return on equity of 29.32% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Haemonetics 7.29% 27.30% 9.59%

Does the media favor LNTH or HAE?

In the previous week, Lantheus had 4 more articles in the media than Haemonetics. MarketBeat recorded 7 mentions for Lantheus and 3 mentions for Haemonetics. Lantheus' average media sentiment score of 0.57 beat Haemonetics' score of 0.28 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, HAE or PODD?

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 2.29 $97.31M $2.02 33.31 Insulet $2.71B 3.64 $247.10M $4.30 33.13

Is HAE or PODD more profitable?

Insulet has a net margin of 10.44% compared to Haemonetics' net margin of 7.29%. Haemonetics' return on equity of 27.30% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.29% 27.30% 9.59% Insulet 10.44% 26.87% 12.01%

Does the media refer more to HAE or PODD?

In the previous week, Insulet had 17 more articles in the media than Haemonetics. MarketBeat recorded 20 mentions for Insulet and 3 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.28 beat Insulet's score of 0.13 indicating that Haemonetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insulet 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, QTRX or HAE?

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quanterix $138.90M 1.06 -$107.15M -$2.36 N/A Haemonetics $1.33B 2.29 $97.31M $2.02 33.31

Is QTRX or HAE more profitable?

Haemonetics has a net margin of 7.29% compared to Quanterix's net margin of -71.86%. Haemonetics' return on equity of 27.30% beat Quanterix's return on equity. Company Net Margins Return on Equity Return on Assets Quanterix -71.86% -23.92% -17.66% Haemonetics 7.29% 27.30% 9.59%

Does the media favor QTRX or HAE?

In the previous week, Haemonetics had 1 more articles in the media than Quanterix. MarketBeat recorded 3 mentions for Haemonetics and 2 mentions for Quanterix. Quanterix's average media sentiment score of 0.93 beat Haemonetics' score of 0.28 indicating that Quanterix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quanterix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Haemonetics (HAE) Competitors

$67.28 +0.24 (+0.36%)

As of 02:29 PM Eastern

Compare

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

Should you buy Haemonetics stock or one of its competitors? MarketBeat compares Haemonetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Haemonetics include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), and Quanterix (QTRX). These companies are all part of the "medical" sector.

How does Haemonetics compare to DexCom?

Haemonetics (NYSE:HAE) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	2.29	$97.31M	$2.02	33.31
DexCom	$4.66B	6.08	$836.30M	$2.34	31.39

Haemonetics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, DexCom has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

DexCom has a net margin of 19.31% compared to Haemonetics' net margin of 7.29%. DexCom's return on equity of 33.33% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.29%	27.30%	9.59%
DexCom	19.31%	33.33%	13.19%

Haemonetics presently has a consensus price target of $77.11, suggesting a potential upside of 14.61%. DexCom has a consensus price target of $82.42, suggesting a potential upside of 12.21%. Given Haemonetics' higher probable upside, research analysts plainly believe Haemonetics is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

In the previous week, DexCom had 25 more articles in the media than Haemonetics. MarketBeat recorded 28 mentions for DexCom and 3 mentions for Haemonetics. DexCom's average media sentiment score of 1.00 beat Haemonetics' score of 0.28 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	21 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

DexCom beats Haemonetics on 13 of the 17 factors compared between the two stocks.

How does Haemonetics compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

HealthEquity has a net margin of 16.39% compared to Haemonetics' net margin of 7.29%. Haemonetics' return on equity of 27.30% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	16.39%	13.86%	8.67%
Haemonetics	7.29%	27.30%	9.59%

HealthEquity presently has a consensus target price of $112.36, indicating a potential upside of 28.85%. Haemonetics has a consensus target price of $77.11, indicating a potential upside of 14.61%. Given HealthEquity's stronger consensus rating and higher possible upside, equities research analysts clearly believe HealthEquity is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

99.6% of HealthEquity shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.6% of HealthEquity shares are held by insiders. Comparatively, 1.8% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, HealthEquity had 11 more articles in the media than Haemonetics. MarketBeat recorded 14 mentions for HealthEquity and 3 mentions for Haemonetics. HealthEquity's average media sentiment score of 0.69 beat Haemonetics' score of 0.28 indicating that HealthEquity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HealthEquity has higher earnings, but lower revenue than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.31B	5.57	$215.20M	$2.46	35.45
Haemonetics	$1.33B	2.29	$97.31M	$2.02	33.31

HealthEquity has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Summary

HealthEquity beats Haemonetics on 10 of the 16 factors compared between the two stocks.

How does Haemonetics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 1.8% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Lantheus had 4 more articles in the media than Haemonetics. MarketBeat recorded 7 mentions for Lantheus and 3 mentions for Haemonetics. Lantheus' average media sentiment score of 0.57 beat Haemonetics' score of 0.28 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.21	$233.56M	$4.15	24.05
Haemonetics	$1.33B	2.29	$97.31M	$2.02	33.31

Lantheus presently has a consensus price target of $101.86, indicating a potential upside of 2.07%. Haemonetics has a consensus price target of $77.11, indicating a potential upside of 14.61%. Given Haemonetics' higher possible upside, analysts clearly believe Haemonetics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Lantheus has a net margin of 18.05% compared to Haemonetics' net margin of 7.29%. Lantheus' return on equity of 29.32% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Haemonetics	7.29%	27.30%	9.59%

Lantheus has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Summary

Lantheus beats Haemonetics on 11 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Insulet?

Haemonetics (NYSE:HAE) and Insulet (NASDAQ:PODD) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Insulet has a net margin of 10.44% compared to Haemonetics' net margin of 7.29%. Haemonetics' return on equity of 27.30% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.29%	27.30%	9.59%
Insulet	10.44%	26.87%	12.01%

In the previous week, Insulet had 17 more articles in the media than Haemonetics. MarketBeat recorded 20 mentions for Insulet and 3 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.28 beat Insulet's score of 0.13 indicating that Haemonetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insulet	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.7% of Haemonetics shares are held by institutional investors. 1.8% of Haemonetics shares are held by insiders. Comparatively, 0.4% of Insulet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	2.29	$97.31M	$2.02	33.31
Insulet	$2.71B	3.64	$247.10M	$4.30	33.13

Haemonetics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Insulet has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Haemonetics currently has a consensus price target of $77.11, indicating a potential upside of 14.61%. Insulet has a consensus price target of $252.04, indicating a potential upside of 76.90%. Given Insulet's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Insulet	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.74

Summary

Insulet beats Haemonetics on 11 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Quanterix?

Quanterix (NASDAQ:QTRX) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Quanterix has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Quanterix currently has a consensus price target of $4.00, suggesting a potential upside of 28.41%. Haemonetics has a consensus price target of $77.11, suggesting a potential upside of 14.61%. Given Quanterix's higher probable upside, analysts clearly believe Quanterix is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	1.06	-$107.15M	-$2.36	N/A
Haemonetics	$1.33B	2.29	$97.31M	$2.02	33.31

Haemonetics has a net margin of 7.29% compared to Quanterix's net margin of -71.86%. Haemonetics' return on equity of 27.30% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-71.86%	-23.92%	-17.66%
Haemonetics	7.29%	27.30%	9.59%

86.5% of Quanterix shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 1.8% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Haemonetics had 1 more articles in the media than Quanterix. MarketBeat recorded 3 mentions for Haemonetics and 2 mentions for Quanterix. Quanterix's average media sentiment score of 0.93 beat Haemonetics' score of 0.28 indicating that Quanterix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quanterix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Haemonetics beats Quanterix on 14 of the 17 factors compared between the two stocks.

Get Haemonetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HAE vs. The Competition

Export

Metric	Haemonetics	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$3.06B	$8.19B	$6.42B	$23.16B
Dividend Yield	N/A	2.53%	2.75%	4.07%
P/E Ratio	33.30	16.21	21.29	30.85
Price / Sales	2.29	6.80	562.18	24.58
Price / Cash	8.86	17.12	43.49	24.96
Price / Book	3.84	4.12	10.61	4.80
Net Income	$97.31M	$224.05M	$3.56B	$1.07B
7 Day Performance	2.75%	4.09%	3.36%	1.34%
1 Month Performance	14.05%	7.69%	6.63%	3.05%
1 Year Performance	-0.83%	3.07%	36.99%	27.31%

Haemonetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HAE Haemonetics	2.7575 of 5 stars	$67.28 +0.4%	$77.11 +14.6%	-0.9%	$3.06B	$1.33B	33.30	3,009	Analyst Forecast
DXCM DexCom	4.3338 of 5 stars	$72.10 flat	$82.21 +14.0%	-16.8%	$27.82B	$4.66B	30.81	11,000	Positive News Analyst Forecast Insider Trade
HQY HealthEquity	4.2283 of 5 stars	$88.11 flat	$111.79 +26.9%	-10.8%	$7.39B	$1.31B	35.82	2,814	Trending News Earnings Report Analyst Forecast
LNTH Lantheus	2.2194 of 5 stars	$103.00 flat	$99.71 -3.2%	+34.3%	$6.71B	$1.54B	24.82	1,193	Analyst Forecast
PODD Insulet	4.2891 of 5 stars	$154.87 flat	$254.96 +64.6%	-55.9%	$10.73B	$2.71B	36.02	5,400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:HAE) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Summary

How does Haemonetics compare to HealthEquity?

Summary

How does Haemonetics compare to Lantheus?

Summary

How does Haemonetics compare to Insulet?

Summary

How does Haemonetics compare to Quanterix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Do institutionals & insiders hold more shares of HAE or DXCM?

Which has preferable earnings & valuation, HAE or DXCM?

Which has more volatility and risk, HAE or DXCM?

Is HAE or DXCM more profitable?

Do analysts prefer HAE or DXCM?

Does the media prefer HAE or DXCM?

Summary

How does Haemonetics compare to HealthEquity?

Is HQY or HAE more profitable?

Do analysts prefer HQY or HAE?

Do institutionals and insiders have more ownership in HQY or HAE?

Does the media refer more to HQY or HAE?

Which has higher valuation & earnings, HQY or HAE?

Which has more volatility & risk, HQY or HAE?

Summary

How does Haemonetics compare to Lantheus?

Do insiders and institutionals have more ownership in LNTH or HAE?

Does the media favor LNTH or HAE?

Which has higher valuation and earnings, LNTH or HAE?

Do analysts rate LNTH or HAE?

Is LNTH or HAE more profitable?

Which has more risk & volatility, LNTH or HAE?

Summary

How does Haemonetics compare to Insulet?

Is HAE or PODD more profitable?

Does the media refer more to HAE or PODD?

Do institutionals and insiders have more ownership in HAE or PODD?

Which has better earnings & valuation, HAE or PODD?

Which has more volatility & risk, HAE or PODD?

Do analysts prefer HAE or PODD?

Summary

How does Haemonetics compare to Quanterix?

Which has more volatility and risk, QTRX or HAE?

Do analysts rate QTRX or HAE?

Which has better valuation and earnings, QTRX or HAE?

Is QTRX or HAE more profitable?

Do insiders & institutionals hold more shares of QTRX or HAE?

Does the media favor QTRX or HAE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools